Improving CAR T-Cell Persistence
Over the last decade remarkable progress has been made in enhancing the efficacy of CAR T therapies. However, the clinical benefits are still limited, especially in solid tumors. Even in hematological settings, patients that respond to CAR T therapies remain at risk of relapsing due to several facto...
Main Authors: | Violena Pietrobon, Lauren Anne Todd, Anghsumala Goswami, Ofir Stefanson, Zhifen Yang, Francesco Marincola |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-10-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/19/10828 |
Similar Items
-
Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
by: Benno Lickefett, et al.
Published: (2023-12-01) -
Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma
by: Felix Korell, et al.
Published: (2021-04-01) -
CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence
by: Wei Wei, et al.
Published: (2023-08-01) -
Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
by: Franziska Marquard, et al.
Published: (2023-11-01) -
Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment
by: Zhifen Yang, et al.
Published: (2023-02-01)